Troglitazone
- TRADE NAMES: Prelay (Sankyo); Rezulin (Pfizer)
- INDICATIONS: Management of Type II diabetes (noninsulin-dependent diabetes mellitus (NIDDM) also known as adult-onset diabetes)
- CLASS: Antidiabetic, CYP3A4 inducer, Thiazolidinedione
- HALF-LIFE: 16–34 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cholestyramine, Digoxin, Terfenadine
PREGNANCY CATEGORY: B
Troglitazone should not be used in Type I diabetes or for the treatment of diabetic keto-acidosis.
Not available in USA, UK or Japan.
HEPATOTOXICITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric